NIAGARA: Impact of pCR on Long-Term Outcomes
NIAGARA: Impact of pCR on Long-Term Outcomes

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Matthew Galsky, MD, of Icahn School of Medicine at Mount Sinai, highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.

He also considers the additional follow-up analyses planned for NIAGARA, and what approach might be available to tease out the benefit of the neoadjuvant combination in this patient population.

Advertisement

Latest News

Radical Prostatectomy Versus Radiotherapy in High-Risk Prostate Cancer
Radical Prostatectomy Versus Radiotherapy in High-Risk Prostate Cancer
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | February 19, 2025
Newly presented research on the CALGB-90203 (PUNCH) and NRG/RTOG-0521 trials are discussed.
JAVEMACS: JAVELIN Bladder 100 Subset Review - Real-World Effectiveness of First-Line Avelumab in Japanese Patients
JAVEMACS: JAVELIN Bladder 100 Subset Review - Real-World Effectiveness of First-Line Avelumab in Japanese Patients
Hiroshi Kitamura, MDUrothelial Carcinoma | February 19, 2025
Dr. Kitamura shares the differences observed between the JAVEMACS and JAVELIN Bladder 100 patient cohorts.
The Role of Metastasis-Directed Radiotherapy in Oligometastatic Bladder and Upper Tract Cancer
The Role of Metastasis-Directed Radiotherapy in Oligometastatic Bladder and Upper Tract Cancer
Comron Hassanzadeh, MDUrothelial Carcinoma | February 19, 2025
Dr. Hassanzadeh elaborates on the benefits of MDT for patients with progressive or de novo disease.
Efficacy of Durvalumab Plus Savolitinib in MET-Driven Papillary Renal Cancer: Insights From CALYPSO
Efficacy of Durvalumab Plus Savolitinib in MET-Driven Papillary Renal Cancer: Insights From CALYPSO
Emily MenendeznccRCC | February 19, 2025
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
Neoadjuvant Pembrolizumab and aMVAC for Non-Urothelial MIBC: Does This Combination Improve Outcomes?
Neoadjuvant Pembrolizumab and aMVAC for Non-Urothelial MIBC: Does This Combination Improve Outcomes?
Petros Grivas, MD, PhDUrothelial Carcinoma | February 19, 2025
Drs. Grivas, Khaki, and Raychaudhuri discuss a phase II trial evaluating pembrolizumab plus aMVAC for non-UC MIBC.
PORTOS Validation in Phase 3 Trials: Gene Signature Predictor of Dose-Response to Prostate Radiation
PORTOS Validation in Phase 3 Trials: Gene Signature Predictor of Dose-Response to Prostate Radiation
Shuang Zhao, MDProstate Cancer | February 19, 2025
Dr. Zhao shares how PORTOS predicts radiation dose response in prostate cancer and how it can be integrated into practice.
Real-World Safety of First-Line Therapies for la/mUC in the US
Real-World Safety of First-Line Therapies for la/mUC in the US
Amanda Nizam, MDUrothelial Carcinoma | February 20, 2025
Dr. Nizam touched on her study of real-world safety of first-line therapies for locally advanced or metastatic UC in the US.
Erdafitinib With EV Following Platinum, PD-1/L1 Inhibitors for mUC with FGFR3/2 Alterations
Erdafitinib With EV Following Platinum, PD-1/L1 Inhibitors for mUC with FGFR3/2 Alterations
Rohit K. Jain, MB, BS, MDUrothelial Carcinoma | February 20, 2025
Dr. Jain spoke to the rationale for combining erdafitinib with EV in mUC patients with FGFR3/2 genetic alterations.
Survival Outcomes Data From Neoadjuvant Chemotherapy and Surgical Consolidation in cN+ UTUC
Survival Outcomes Data From Neoadjuvant Chemotherapy and Surgical Consolidation in cN+ UTUC
Joon Kyung Kim, MDUrothelial Carcinoma | February 18, 2025
Dr. Kim discusses systemic therapy and surgical consolidation in node-positive upper tract urothelial carcinoma treatment.
Evaluating Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: Insights From the ABLE-22 Trial
Evaluating Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: Insights From the ABLE-22 Trial
Sia Daneshmand, MDUrothelial Carcinoma | February 18, 2025
The ABLE-22 trial evaluates nadofaragene firadenovec alone and in combination for BCG-unresponsive NMIBC.
Patient-Reported Outcomes From TiNivo-2 Highlight Quality-of-Life Considerations in RCC Treatment
Patient-Reported Outcomes From TiNivo-2 Highlight Quality-of-Life Considerations in RCC Treatment
Brandon TwyfordRenal Cell Carcinoma | February 18, 2025
The study found no PFS benefit for tivozanib plus nivolumab in RCC post-ICI, but tivozanib maintained quality of life.
Neoadjuvant Durvalumab Plus Chemotherapy Shows Promise in Upper Tract Urothelial Carcinoma
Neoadjuvant Durvalumab Plus Chemotherapy Shows Promise in Upper Tract Urothelial Carcinoma
Brandon TwyfordUrothelial Carcinoma | February 18, 2025
Neoadjuvant durvalumab plus chemotherapy shows promising pathologic response rates, favorable safety profile in UTUC.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Brad McGregor, MDMuscle Invasive Urothelial Carcinoma | August 14, 2024
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Christopher Kane, MDProstate Cancer | June 20, 2024
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
MoonRISe-1: TAR-210 for Intermediate-Risk NMIBC
MoonRISe-1: TAR-210 for Intermediate-Risk NMIBC
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | May 28, 2024
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Jennifer Miles-Thomas, MD, FPMRS – Spearheading Female Urology, Health, and Innovation
Jennifer Miles-Thomas, MD, FPMRS – Spearheading Female Urology, Health, and Innovation
Jennifer Miles-Thomas, MD, FPMRSAUA 2024 | April 30, 2024
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mHSPC/mCSPC
mHSPC/mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC
Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC
Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
# Posted on February 19, 2025
# Uromigos-Kidney Cancer
Episode 390: ASCO GU 2025 - Pembro-Based Doublets in Refractory RCC and COSMIC-313 OS Update
Episode 390: ASCO GU 2025 - Pembro-Based Doublets in Refractory RCC and COSMIC-313 OS Update
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
# Posted on February 19, 2025
# Uromigos-Kidney Cancer
Episode 388: ASCO GU 2025 - FGFR3 Inhibition With LOXO-435 in Urothelial Cancer
Episode 388: ASCO GU 2025 - FGFR3 Inhibition With LOXO-435 in Urothelial Cancer
Dr. Gopa Iyer of Memorial Sloan Kettering Cancer Center joins the show to discuss his initial results.
# Posted on February 19, 2025
# Uromigos-Bladder Cancer

Conference Coverage

Live meeting highlights

Radical Prostatectomy Versus Radiotherapy in High-Risk Prostate Cancer
Christopher Wallis, MD, PhD, FRCSCProstate Cancer | February 19, 2025
Newly presented research on the CALGB-90203 (PUNCH) and NRG/RTOG-0521 trials are discussed.
View More
JAVEMACS: JAVELIN Bladder 100 Subset Review - Real-World Effectiveness of First-Line Avelumab in Japanese Patients
Hiroshi Kitamura, MDUrothelial Carcinoma | February 19, 2025
Dr. Kitamura shares the differences observed between the JAVEMACS and JAVELIN Bladder 100 patient cohorts.
View More
The Role of Metastasis-Directed Radiotherapy in Oligometastatic Bladder and Upper Tract Cancer
Comron Hassanzadeh, MDUrothelial Carcinoma | February 19, 2025
Dr. Hassanzadeh elaborates on the benefits of MDT for patients with progressive or de novo disease.
View More
Efficacy of Durvalumab Plus Savolitinib in MET-Driven Papillary Renal Cancer: Insights From CALYPSO
Emily MenendeznccRCC | February 19, 2025
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
Read More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |